You are here

Article Text

Article menu
Download PDFPDF
Aetiology/Harm
Case–control
Cotrimoxazole is associated with sudden death in older patients receiving inhibitors of renin–angiotensin system
  1. Raya E Kheirbek1,
  2. Nawar Shara2
  1. 1VA Medical Center, Washington DC, USA;
  2. 2MedStar Health Research Institute, Hyattsville, Maryland, USA
  1. Correspondence to : Dr Raya E Kheirbek, VA Medical Center, 50 Irving Street North West, Washington DC 20422, USA; raya.kheirbek{at}va.gov

http://dx.doi.org/10.1136/ebmed-2014-110133

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Fralick M, Macdonald EM, Gomes T, et al. Canadian Drug Safety and Effectiveness Research Network. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014;349:g6196OpenUrlAbstract/FREE Full Text.

    Context

    ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly prescribed to older patients with hypertension, heart failure (HF) and chronic kidney disease (CKD) and may increase serum potassium (K) levels. Cotrimoxazole, a common antibiotic used to treat urinary tract infections, may also raise serum K levels, especially in patients also taking other drugs that raise serum K …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.